All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Asthma is a disease characterized by airway hyperresponsiveness (AHR) leading to bronchoconstriction and airway inflammation, which result in ventilation deficiencies throughout the lungs. Although still incompletely understood, AHR tends to occur more in people that have a diminished capacity to maximally dilate their airways with a deep inspiration (DI) \[[@pone.0142738.ref001]--[@pone.0142738.ref006]\]. Also, prohibiting DIs for extended periods of time seems to enhance AHR \[[@pone.0142738.ref007], [@pone.0142738.ref008]\] and increase airway narrowing in healthy individuals \[[@pone.0142738.ref009], [@pone.0142738.ref010]\]. Additionally, when exposed to bronchial provocation, airways bronchodilate following DIs \[[@pone.0142738.ref005]\] in healthy subjects with the degree of recovery decreasing with asthma severity \[[@pone.0142738.ref011]\].

Recent studies have found that AHR is also related to the degree of ventilation heterogeneity at baseline \[[@pone.0142738.ref012], [@pone.0142738.ref013]\]. However, these studies employed an indirect method of quantifying ventilation heterogeneity using a multi-breath nitrogen washout (MNBW) technique \[[@pone.0142738.ref012]--[@pone.0142738.ref016]\]. The MBNW technique provides neither spatial nor specific regional information. Furthermore, recent modeling studies have questioned the ability of this technique to detect poorly ventilated or completely non-ventilated areas \[[@pone.0142738.ref017]\]. On the other hand, traditional methods of direct visualization such as computed tomography (CT) imaging \[[@pone.0142738.ref018]\] and positron emission tomography (PET) \[[@pone.0142738.ref019]--[@pone.0142738.ref022]\] require invasive radiation exposure making them unsuitable for clinical evaluation of ventilation heterogeneity. Recently, Hyperpolarized Helium-3 MRI (HP ^3^He-MRI) has emerged as a novel imaging modality for probing airway conditions in a number of obstructive pulmonary diseases \[[@pone.0142738.ref023]--[@pone.0142738.ref032]\]. In addition to its lack of radiation exposure, it provides a direct visualization of ventilation enabling quantification of lung volumes \[[@pone.0142738.ref028], [@pone.0142738.ref030]\] as well as characterization of ventilation distributions \[[@pone.0142738.ref023], [@pone.0142738.ref032]\] and applications to computational modeling \[[@pone.0142738.ref023]\].

Indirect methods of quantifying baseline ventilation heterogeneity via analysis of MBNW have shown a relationship to AHR \[[@pone.0142738.ref012], [@pone.0142738.ref013]\]. Direct lung imaging, in principal, can be used to spatially identify and quantify ventilation heterogeneity. The goal of this study was to use our advances in imaging analysis to establish a quantitative relationship between ventilation heterogeneity and the dynamic changes in lung mechanical function and airway hyperresponsiveness in asthmatic subjects. To this end, here we introduce and apply the coefficient of variation (CV) of ventilated volume fraction (VVF), evaluated from static HP ^3^He-MRI images, as a measure of ventilation heterogeneity, and we correlate this index with measurements of dynamic lung mechanics and AHR in healthy and asthmatic subjects.

Materials and Methods {#sec002}
=====================

Subject Enrollment and Experimental Protocol {#sec003}
--------------------------------------------

The research protocol used in this study was approved by both Boston University and Brigham and Women's Hospital Institutional Review Boards. Written informed consent was obtained from all recruits, which consisted of four healthy subjects and nine asthmatic subjects. Before the day of the study visit, airway reactivity was assessed in all subjects by interpolating a methacholine (MCh) dose-response curve to obtain the concentration of agonist that elicits a 20% decrease in the subject's forced expiratory volume in one second (FEV~1~) compared to baseline (PC~20~). Doses used to determine the PC~20~ did not exceed a maximum dose of 25.0 mg/ml. For our protocol, healthy subjects were nonsmokers with no history of respiratory diseases and exhibited PC~20~ values of \>25 mg/mL. Mild-to-moderate asthmatics were defined as physician-diagnosed asthmatics exhibiting a FEV~1~ ≥ 60% predicted, without inhaled or oral corticosteroids, asthma symptoms less than 7 times per week requiring β~2~-agonist use, and well-controlled on low dose regimen of inhaled corticosteroids. The demographics are detailed in [Table 1](#pone.0142738.t001){ref-type="table"}.

10.1371/journal.pone.0142738.t001

###### Subject demographics.

![](pone.0142738.t001){#pone.0142738.t001g}

                  Subject   Gender   Age, yr   Height, cm   Weight, kg   FEV~1~, %pred   PC~20~ MCh (mg/mL)
  --------------- --------- -------- --------- ------------ ------------ --------------- --------------------
  **Healthy**                                                                            
                  H1        M        22        180          91           100             \>25
                  H2        F        25        150          53           108             \>25
                  H3        F        24        165          54           115             \>25
                  H4        M        47        180          100          117             \>25
  **Asthmatic**                                                                          
                  A1        F        32        173          70           90              10.60
                  A2        F        38        160          69           76              \>25
                  A3        M        31        165          66           83              4.10
                  A4        F        30        160          48           64              0.80
                  A5        M        36        183          100          85              7.99
                  A6        F        45        180          86           85              0.78
                  A7        M        21        178          81           84              0.27
                  A8        F        29        168          58           84              1.25
                  A9        M        30        173          82           68              12.47

An on-site Pulmonologist monitored all our measurements. First, baseline spirometry (Micro Medical: Microlab 3000 series or Microloop 3535S) was measured from all subjects, followed by placement of an esophageal balloon catheter to estimate intrapleural pressure. Baseline (PreMch) lung mechanics were then measured following which baseline HP ^3^He-MRI images were acquired. Thereafter, a MCh-challenge (S&M Instrument Company, Inc., DSM2030 Dosimeter and DeVilbiss 646 Nebulizer) was administered to induce bronchoconstriction. The MCh concentrations were diluent (0.078 mg/ml, 0.156 mg/ml, 0.3125 mg/ml, 0.625 mg/ml, 1.25 mg/ml, 2.5 mg/ml, 5.0 mg/ml, 10.0 mg/ml, and 25.0 mg/ml). Every other MCh concentration in the challenge could be skipped until 10.0 mg/ml for healthy subjects or until the concentration one order of magnitude below the asthmatic subject's known PC~20~ dose measured on screening day. This was due to time constraints with the polarization of HP ^3^He. The MCh challenge ended upon eliciting an FEV~1~ decrease of 20% or the 25.0 mg/ml dose. Following the MCh-challenge (PostMch), subjects were asked to refrain from taking any deep inspirations (DIs) until otherwise instructed. Lung mechanics were measured again, and HP ^3^He-MRI images were reacquired. Finally, the subject was instructed to sit in an upright position and take five DIs (PostDI) after which they were reinserted into the MRI for the final set of image acquisition. Lung mechanics measurements were then subsequently repeated. A schematic of the protocol is illustrated in [Fig 1](#pone.0142738.g001){ref-type="fig"}.

![Experimental protocol.\
The experiments span three phases: phase I comprises lung mechanics and imaging, PreMch, followed by phase II which entails a Mch-challenge and lung mechanics and imaging, PostMch, and finally phase III which entails lung mechanics measurements and imaging, PostDI.](pone.0142738.g001){#pone.0142738.g001}

Dynamic Lung Mechanics Measurements {#sec004}
-----------------------------------

Dynamic lung resistance (*R* ~*L*~) and lung elastance (*E* ~*L*~) were measured using the Optimal Ventilation Waveform (OVW) technique, as previously described \[[@pone.0142738.ref033]--[@pone.0142738.ref035]\]. Briefly, the technique entails delivering a waveform via a linear motor at seven non-sum, non-difference frequencies ranging from 0.1 to 8 Hz and with phases optimized such that the forcing signal also ventilates the subject with a typical tidal volume per breath. In a seated position, each subject was instructed to relax to allow the ventilator to deliver the OVW over a period of 40--60 seconds. Flow (*Q* ~*ao*~) and pressure (*P* ~*ao*~) were measured at the airway opening, and an esophageal pressure (*P* ~*es*~) was measured via a balloon catheter from which a transpulmonary pressure (*P* ~*tp*~) can be estimated from the difference between *P* ~*ao*~ and *P* ~*es*~. A lung impedance (*Z* ~*L*~ *(ω)*) ([Eq 1](#pone.0142738.e001){ref-type="disp-formula"}) can be calculated in which *R* ~*L*~ would result from the real or in-phase component ([Eq 2](#pone.0142738.e002){ref-type="disp-formula"}) and *E* ~*L*~ would result from the imaginary or out-of-phase component ([Eq 3](#pone.0142738.e003){ref-type="disp-formula"}) in the frequency domain.

![](pone.0142738.e001.jpg){#pone.0142738.e001g}
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From the OVW data we extracted several features that have been shown to be sensitive to airway and tissue conditions and the pattern of airway constriction. Low frequency (0.1 Hz) lung resistance (R~low~) represents the combined impact of viscoelastic tissues and any heterogeneous constriction pattern that might emerge post-challenge. At low frequencies, E~L~, approximates the "quasi-static" tissue elastance of the amount of lung that is ventilated at that frequency neglecting any inertive components due to the accelerative motion of the air in the lung which becomes important at higher frequencies. Thus, low frequency lung elastance, E~low~, can increase either due to an inherent increase in tissue stiffness or because of heterogeneous airway constriction preventing substantive portion of the lung tissue from being ventilated (e.g., a smaller lung). High frequency (8 Hz) lung resistance (R~high~) reflects primarily the net overall conductive airway resistance of the airway tree alone \[[@pone.0142738.ref033], [@pone.0142738.ref034]\]. The frequency dependence (R~het~) is calculated from the difference between R~low~ and R~high~ and reflects the impact of heterogeneous constriction \[[@pone.0142738.ref003], [@pone.0142738.ref036]\].

Image Acquisition {#sec005}
-----------------

For our image acquisition, each subject was instructed to inhale a \~1 liter mixture of 33% HP ^3^He and 67% N~2~ from functional residual capacity (FRC). Subjects were instructed to try to inhale the 1 L of gas within a 5- to 8-second period with each scan spanning a total of about 11 seconds. Images were acquired on a General Electric Signa LX 1.5 MRI scanner equipped with a heterodyne system which included frequency mixers to image at the ^3^He NMR frequency of 48.65 Hz. The system interfaced with a flexible quadrature lung coil (Clinical MR Solutions, Brookfield, WI) tuned to the same frequency. Hyperpolarization of the ^3^He gas was initiated through a collision spin exchange with vaporized Rubidium optically pumped using a custom-built polarizer. The scans employed a Fast Gradient Echo pulse sequence that compiled coronal multi-slice images with a field of view of 46 cm, 128 x 256 matrix dimensions (zero-padded to 256 x 256), 13-mm slice thickness, 0-mm gap between slices, 1.8-mm in-slice resolution, 31.25-kHz bandwidth, 14--18°flip angle, TE/TR 1.228 ms/50-75 ms, and interleaved data acquisition. Subjects were instructed to hold still during image acquisition as small movements can affect the quality of images obtained. Approximately 8--14 slices were compiled for each subject depending on the anterior to posterior depth of the lung to capture the entire coronal lung field.

Image Processing {#sec006}
----------------

Ventilated airspaces were segmented through a recently developed semiautomatic algorithm described elsewhere \[[@pone.0142738.ref030]\]. Briefly, it comprises a three step process involving a statistical denoising scheme, followed by a clustering of ventilation classes, and finally a removal of the trachea and the major airways. The remaining non-background pixel intensities were then correspondingly adjusted for signal bias as: $${\hat{S}}_{i,j,k} = \sqrt{S_{i,j,k}^{2} - \frac{2}{\pi}{\overline{S}}_{BG}^{2}}$$ where ${\hat{S}}_{i,j,k}$ is the corrected pixel intensity, ${\overline{S}}_{BG}$ is the average pixel intensity of the sampled noise region, *i* and *j* are the pixel indices and *k* is the slice index \[[@pone.0142738.ref037], [@pone.0142738.ref038]\]. The sum of the signal intensities, $\sum\limits_{i,j,k}{\hat{S}}_{i,j,k}$, represent the amount of inhaled gas. By calculating a fraction of each corresponding voxel, ${\hat{S}}_{i,j,k}$, we obtain a fraction of inhaled gas, termed ventilated volume fraction (*VVF* ~*i*,*j*,*k*~)\[[@pone.0142738.ref023], [@pone.0142738.ref032]\] given as: $$VVF_{i,j,k} = \frac{{\hat{S}}_{i,j,k}}{\sum\limits_{i,j,k}{\hat{S}}_{i,j,k}}$$

A corresponding CV of the VVF was calculated from the standard deviation of VVF (σ~*VVF*~) and the mean VVF (*μ* ~*VVF*~) for each condition, PreMch, PostMch, and PostDI as follows: $$CV_{VVF} = \frac{\sigma_{VVF}}{\mu_{VVF}}$$

Statistical Analysis {#sec007}
--------------------

Data was collected and HP ^3^He-MRI images were analyzed through a self-developed image processing algorithm on MATLAB (MathWorks Inc., MA). Linear regressions and statistical analyses were obtained through SigmaPlot (Systat Software, Inc., CA). A paired two-tailed student's *t*-test was used to assess for significant differences between each condition (PreMch, PostMch, PostDI), and an unpaired two-tailed student's *t*-test was used to assess for significant differences between each subgroup (healthy and asthmatics). A probability of *P* \< 0.05 with a statistical power ≥ 0.8 was considered statistically significant.

Results {#sec008}
=======

Patchy areas of high and very low ventilation are evident following induced bronchoconstriction in both healthy and asthmatic subjects ([Fig 2](#pone.0142738.g002){ref-type="fig"}). Following a series of DIs whereas ventilation recovery visually occurs in the healthy subject, areas of poor ventilation are still prevalent in the asthmatic subject. A corresponding CV was calculated and a summary is shown in [Fig 3](#pone.0142738.g003){ref-type="fig"} and in Tables [2](#pone.0142738.t002){ref-type="table"} and [3](#pone.0142738.t003){ref-type="table"}. PreMch healthy subjects maintained a CV of 0.38 ± 0.01 (mean ± SD) which increased to 0.48 ± 0.07, PostMch, and recovered to 0.42 ± 0.02, PostDI. PreMch asthmatic subjects maintained a CV of 0.42 ± 0.05 which increased to 0.51 ± 0.03, PostMch, and recovered only partially to 0.46 ± 0.03, PostDI. However, there was not a statistically significant difference in the CVs PreMch, CVs PostMch, and CVs PostDI between the healthy and asthmatic subjects. In the asthmatic subjects, there was a statistically significant difference between CV PreMch and CV PostMch (*P* \< 0.001), but not between CV PostMch and CV PostDI and between CV PreMch and CV PostDI. However, in the healthy subjects, there was not a statistically significant difference between CV PreMch and CV PostMch, between CV PostMch and CV PostDI, and between CV PreMch and PostDI. The results likely reflect the small number of healthy subjects.

![Single slice ventilation images for a healthy and asthmatic subject for PreMch, PostMch, and PostDI.\
HP ^3^He-MRI images (top row) are first segmented to evaluate for ventilated regions (middle row) and quantified to determine a mapped-out VVF (bottom row). Note the increased pockets of elevated ventilation in both healthy and asthmatics following a Mch-challenge and the lack of recovery for the asthmatic after a series of DIs.](pone.0142738.g002){#pone.0142738.g002}

![CV for PreMch, PostMch, and PostDI conditions with corresponding standard errors.\
Note across all three conditions, the mean CVs for the asthmatic subjects were consistently higher than the mean CVs for the healthy subjects, although not statistically significant. Refer to Tables [2](#pone.0142738.t002){ref-type="table"} and [3](#pone.0142738.t003){ref-type="table"} for statistical significance in comparisons between PreMch, PostMch, and PostDI.](pone.0142738.g003){#pone.0142738.g003}

10.1371/journal.pone.0142738.t002

###### Dynamic lung mechanics and CV for healthy and asthmatic subjects.

![](pone.0142738.t002){#pone.0142738.t002g}

                  Condition   R~low~ (cm H~2~O/L/s) (mean ± SD)                                                               R~high~ (cm H~2~O/L/s) (mean ± SD)                                                             R~het~ (cm H~2~O/L/s) (mean ± SD)                                                               E~low~ (cm H~2~O/L) (mean ± SD)                                                                 CV (mean ± SD)
  --------------- ----------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  **Healthy**                                                                                                                                                                                                                                                                                                                                                                                                                
                  PreMch      3.72 ± 1.58                                                                                     3.23 ± 1.10                                                                                    0.49 ± 0.67                                                                                     7.56 ± 1.93                                                                                     0.38 ± 0.01[^α^](#t002fn001){ref-type="table-fn"} ^,^ [^γ^](#t002fn003){ref-type="table-fn"}
                  PostMch     13.42 ± 8.90                                                                                    5.25 ± 1.95                                                                                    8.15 ± 6.98                                                                                     14.19 ± 6.11                                                                                    0.48 ± 0.07[^α^](#t002fn001){ref-type="table-fn"}
                  PostDI      5.91 ± 2.70                                                                                     4.55 ± 1.60                                                                                    1.36 ± 1.41                                                                                     6.31 ± 2.21                                                                                     0.42 ± 0.02[^γ^](#t002fn003){ref-type="table-fn"}
  **Asthmatic**                                                                                                                                                                                                                                                                                                                                                                                                              
                  PreMch      6.75 ± 3.32[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}    5.10 ± 2.03[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}   1.66 ± 1.83[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}    9.06 ± 2.99[^x^](#t002fn004){ref-type="table-fn"}                                               0.42 ± 0.05[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}
                  PostMch     18.35 ± 4.79[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^y^](#t002fn005){ref-type="table-fn"}   8.31 ± 3.78[^x^](#t002fn004){ref-type="table-fn"}                                              10.04 ± 4.29[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^y^](#t002fn005){ref-type="table-fn"}   17.49 ± 5.54[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^y^](#t002fn005){ref-type="table-fn"}   0.51 ± 0.03[^x^](#t002fn004){ref-type="table-fn"} ^,^ [^y^](#t002fn005){ref-type="table-fn"}
                  PostDI      12.87 ± 5.34[^y^](#t002fn005){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}   7.77 ± 2.47[^z^](#t002fn006){ref-type="table-fn"}                                              5.09 ± 3.50[^y^](#t002fn005){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}    12.08 ± 5.16[^y^](#t002fn005){ref-type="table-fn"}                                              0.46 ± 0.03[^y^](#t002fn005){ref-type="table-fn"} ^,^ [^z^](#t002fn006){ref-type="table-fn"}

^α^denotes statistically significant difference between PreMch and PostMch (*P* \< 0.05) in healthy subjects.

^β^denotes statistically significant difference between PostMch and PostDI (*P* \< 0.05) in healthy subjects.

^γ^denotes statistically significant difference between PreMch and PostDI (*P* \< 0.05) in healthy subjects.

^x^denotes statistically significant difference between PreMch and PostMch (*P* \< 0.05) in asthmatic subjects.

^y^denotes statistically significant difference between PostMch and PostDI (*P* \< 0.05) in asthmatic subjects.

^z^denotes statistically significant difference between PreMch and PostDI (*P* \< 0.05) in asthmatic subjects.

10.1371/journal.pone.0142738.t003

###### Statistical Power for Pairwise Student's *t*-tests.

![](pone.0142738.t003){#pone.0142738.t003g}

              Condition        R~low~ (cm H~2~O/L/s) (mean ± SD)            R~high~ (cm H~2~O/L/s) (mean ± SD)           R~het~ (cm H~2~O/L/s) (mean ± SD)            E~low~ (cm H~2~O/L) (mean ± SD)              CV (mean ± SD)
  ----------- ---------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- --------------------------------------------
  Healthy                                                                                                                                                                                                          
              PreMch-PostMch   0.351                                        0.240                                        0.366                                        0.316                                        0.700[\*](#t003fn001){ref-type="table-fn"}
              PostMch-PostDI   0.181                                        0.050                                        0.270                                        0.454                                        0.240
              PreMch-PostDI    0.127                                        0.578                                        0.069                                        0.398                                        0.756[\*](#t003fn001){ref-type="table-fn"}
  Asthmatic                                                                                                                                                                                                        
              PreMch-PostMch   1.000[\*](#t003fn001){ref-type="table-fn"}   0.464[\*](#t003fn001){ref-type="table-fn"}   1.000[\*](#t003fn001){ref-type="table-fn"}   0.966[\*](#t003fn001){ref-type="table-fn"}   0.997[\*](#t003fn001){ref-type="table-fn"}
              PostMch-PostDI   0.483[\*](#t003fn001){ref-type="table-fn"}   0.050                                        0.649[\*](#t003fn001){ref-type="table-fn"}   0.418[\*](#t003fn001){ref-type="table-fn"}   0.934[\*](#t003fn001){ref-type="table-fn"}
              PreMch-PostDI    0.738[\*](#t003fn001){ref-type="table-fn"}   0.578[\*](#t003fn001){ref-type="table-fn"}   0.620[\*](#t003fn001){ref-type="table-fn"}   0.178[\*](#t003fn001){ref-type="table-fn"}   0.504[\*](#t003fn001){ref-type="table-fn"}

\*Corresponds to statistical power for where *P* \< 0.05

Dynamic lung mechanics for healthy and asthmatic subjects are summarized in [Fig 4](#pone.0142738.g004){ref-type="fig"} and Tables [2](#pone.0142738.t002){ref-type="table"} and [3](#pone.0142738.t003){ref-type="table"}. Under all three conditions, PreMch, PostMch, and PostDI, the mean values of all four parameters, R~low~, R~high~, R~het~, and E~low~, were higher in the asthmatic subjects in comparison to the healthy subjects, although not statistically significant. In the asthmatic subjects, there was a significant difference between PreMch and PostMch for indices of R~low~ (*P* \< 0.001), R~het~ (*P* \< 0.001), and E~low~ (*P* = 0.001), but not R~high~. There was not a significant difference in all four mechanical parameters (R~low~, R~high~, R~het~, and E~low~) between PostMch and PostDI and between PreMch and PostDI in both healthy and asthmatic subjects. Moreover, in the healthy subjects, there was also not a statistically significant difference between PreMch and PostMch. Interestingly, PostDI E~low~, an indicator of the heterogeneity of airway closures, returned to its mean baseline value in the healthy subjects but did not in the asthmatic subjects. However, the difference between E~low~ PostMch and E~low~ PostDI was not statistically significant in both healthy and asthmatic subjects.

![Dynamic lung mechanics measurements for PreMch, PostMch, and PostDI conditions, for R~low~ (a.), R~high~ (b.), R~het~ (c.), and E~low~ (d.) with corresponding standard errors.\
Again, across all three conditions, the mean values of all four indices of dynamic lung mechanics, R~low~, R~high~, R~het~, and E~low~ for the asthmatic subjects were consistently higher than those for the healthy subjects, although not statistically significant. Refer to Tables [2](#pone.0142738.t002){ref-type="table"} and [3](#pone.0142738.t003){ref-type="table"} for statistical significance in comparisons between PreMch, PostMch, and PostDI.](pone.0142738.g004){#pone.0142738.g004}

Relationship to Dynamic Lung Mechanics {#sec009}
--------------------------------------

Correlation coefficients were calculated through a least squares linear regression between our image-derived CV of ventilation and measured dynamic lung mechanics, R~low~, R~high~, R~het~, and E~low~ over all subjects. The results are summarized in [Fig 5](#pone.0142738.g005){ref-type="fig"}. Over all the healthy and asthmatic subjects, CV was significantly correlated with R~low~ (*R* = 0.647, *P* \< 0.0001), R~het~ (*R* = 0.668, *P* \< 0.0001), and E~low~ (*R* = 0.547, *P* = 0.003). However, CV was found to have a low correlation to R~high~ (*R* = 0.378, *P* = 0.02). For the healthy subjects only, CV was significantly correlated to R~low~ (*R* = 0.775, *P* = 0.003), R~high~ (*R* = 0.581, *P* = 0.05), and R~het~ (*R* = 0.794, *P* = 0.002), but not significantly correlated to E~low~ (*R* = 0.543, *P* = 0.07). For the asthmatic subjects only, CV was significantly correlated to R~low~ (*R* = 0.541, *P* = 0.004), R~het~ (*R* = 0.573, *P* = 0.002), and E~low~ (*R* = 0.505, *P* = 0.007), but not significantly correlated to R~high~ (*R* = 0.257, *P* = 0.20).

![Association between CV and dynamic lung mechanics indices, R~low~ (a.), R~high~ (b.), R~het~ (c.), and E~low~ (d.).\
Note that while there was a significant correlation between CV and R~low~ (a.), R~het~ (c.), and E~low~ (d.), there was little correlation seen with R~high~ (b.) over all healthy subjects and mild-to-moderate asthmatics.](pone.0142738.g005){#pone.0142738.g005}

Relationship to AHR {#sec010}
-------------------

Over the nine asthmatic subjects, AHR was evaluated from measurements of PC~20~. One asthmatic subject, however, exhibited a PC~20~ \> 25 mg/ml and hence was excluded in our analysis. The results are illustrated in [Fig 6](#pone.0142738.g006){ref-type="fig"}. In the eight asthmatic subjects examined, PreMch CV showed a strong correlation to PC~20~ (*R* = -0.798, *P* \< 0.0001). This correlation was not exhibited in PreMch measurements of dynamic lung mechanics, R~low~ (*R* = 0.16, *P* = 0.68), R~high~ (*R* = 0.29, *P* = 0.46), R~het~ (*R* = 0.038, *P* = 0.92), and E~low~ (*R* = 0.20, *P* = 0.60).

![Baseline CV evaluated from HP ^3^He-MRI images is a predictor of AHR.\
There is a negative correlation between the baseline levels of CV and the PC~20~ dose in the asthmatic subjects. Subjects with a greater degree of baseline ventilation heterogeneity required a lower dose of agonist to achieve a 20% drop in FEV~1~ indicating the possibility of AHR when the subject is exposed to agonist.](pone.0142738.g006){#pone.0142738.g006}

Discussion {#sec011}
==========

Ventilation heterogeneity continues to be a fundamental characteristic of asthma that has been shown to be a predictor of AHR \[[@pone.0142738.ref012], [@pone.0142738.ref013]\]. It has been extended to clinical applications of tracking responses to asthma therapy, specifically to the dose titration of inhaled corticosteroids \[[@pone.0142738.ref039]\]. Whereas indirect methods of determining ventilation heterogeneity through a MBNW technique is restricted by the lack of spatial information and its inability of detecting poorly ventilated areas \[[@pone.0142738.ref012]--[@pone.0142738.ref017]\], direct modalities of imaging run the risk of radiation exposure \[[@pone.0142738.ref018]--[@pone.0142738.ref022]\]. As a noninvasive imaging modality, HP ^3^He-MRI has emerged as a feasible alternative in visualizing the degree of ventilation heterogeneity.

Relationship to Dynamic Lung Mechanics and AHR {#sec012}
----------------------------------------------

Thus far, using qualitative methods of analysis, it has been shown that the number and size of ventilation defects rendered through HP ^3^He-MRI are directly correlated to the degree of clinical severity \[[@pone.0142738.ref025]--[@pone.0142738.ref027]\]. A majority of these defects remained persistent with time and with repeated bronchoconstriction \[[@pone.0142738.ref025], [@pone.0142738.ref026]\]. Since then, there have been a number of advancements in HP ^3^He-MRI with the emergence of quantitative methods to extract detailed structure-to-function relationships in asthma in both humans \[[@pone.0142738.ref023], [@pone.0142738.ref024], [@pone.0142738.ref030], [@pone.0142738.ref032]\] and animals \[[@pone.0142738.ref040]--[@pone.0142738.ref043]\]. For example, recent efforts have calculated a characteristic index to quantify the degree of ventilation heterogeneity \[[@pone.0142738.ref023], [@pone.0142738.ref030], [@pone.0142738.ref032]\]. What has not been established is if and how this index relates to the overall level of mechanical dysfunction and degree of AHR.

Our methods applied a semiautomated approach to the segmentation of ventilated airspaces \[[@pone.0142738.ref030]\] leading to a novel index to quantify the degree of heterogeneity throughout the imaged lung. Hence, we can quantitatively relate such heterogeneity to alterations in dynamic mechanical lung function sensitive to airways, tissues, and the degree of heterogeneous constriction \[[@pone.0142738.ref003], [@pone.0142738.ref020], [@pone.0142738.ref021], [@pone.0142738.ref033],[@pone.0142738.ref034],[@pone.0142738.ref036]\] as well as the overall reactivity (PC~20~) \[[@pone.0142738.ref004], [@pone.0142738.ref012], [@pone.0142738.ref015]\]. Similar to prior studies \[[@pone.0142738.ref007]\], we found that both healthy subjects that withhold DIs and mild-to-moderate asthmatics bronchoconstricted when exposed to airway agonist. In both healthy subjects and mild-to-moderate asthmatics, the degree of ventilation heterogeneity was correlated to the degree of mechanical heterogeneity of bronchoconstriction reflected by the indices of R~low~, R~het~, and E~low~ ([Fig 5](#pone.0142738.g005){ref-type="fig"}) but much less so to the parameter that reflects only the overall level of constriction averaged throughout the airway tree, R~high~. Both R~low~ and E~low~ reflect the mechanical properties of the lung periphery, particularly from contributions of the viscoelastic tissue properties and of the consequences of heterogeneous peripheral constriction \[[@pone.0142738.ref033], [@pone.0142738.ref034]\]. This finding was not evident from prior studies with MBNW \[[@pone.0142738.ref013]\], but that study only assessed mechanics at frequencies above 5 Hz which is not sensitive to the pattern of airway constriction whereas lower frequencies are. This latter frequency range permits more explicit insight on the separation of airway and tissue properties \[[@pone.0142738.ref033], [@pone.0142738.ref034]\]. For example, R~het~ which captures the degree of frequency dependence in dynamic lung resistance (R~L~) is consistent with heterogeneous constriction patterns \[[@pone.0142738.ref003], [@pone.0142738.ref036]\]. Together, these findings suggest a peripheral rather than central airway involvement in ventilation heterogeneity.

Most interesting was that utilizing a PC~20~ as an index for AHR, we demonstrated a strong link between baseline ventilation heterogeneity and the existence of AHR which was not seen in baseline measurements of dynamic lung mechanics. This is a new and potentially important finding. It suggests if the crucial component leading to enhanced AHR is the underlying airway conditions that have already created some level of abnormal ventilation patterns prior to provocation. Thus, if an otherwise asymptomatic asthmatic were to be exposed to a contractile stimulus (e.g., due to exposure to an allergen or enhanced inflammatory mediators), an existing slightly abnormal pattern of ventilation will enhance the subsequent degradation in mechanical lung function far more so than if this asthmatic exhibited a more uniform ventilation. Such a finding seems to suggest an exacerbation of the instability mechanisms proposed by Venegas *et al*. in symmetric airway trees \[[@pone.0142738.ref022]\] and by Leary *et al*. in asymmetric airway trees \[[@pone.0142738.ref044]\].

Limitations {#sec013}
-----------

There are some limitations in our comparative analysis. To ensure safety of subjects who participated in our study, we set the maximum inhaled dose of Mch to 25 mg/ml. In some healthy subjects even this maximum dose did not elicit a 20% drop in FEV~1~. Thus, it is important to note that in our statistical comparisons, the degree of bronchoconstriction achieved was not the same among groups. Furthermore, we only recorded FEV~1~ at baseline and do not have measurements of FEV~1~ post-challenge with Mch. However, we did record measurements of R~low~, R~high~, R~het~ and E~low~ as well as calculated the CV in all subjects PostMch. There was not a statistically significant difference in PostMch between healthy and asthmatic subjects. Of the mild-to-moderate asthmatics, one asthmatic subject demonstrated PC~20~ which exceeded the maximum allowable dose of 25 mg/ml, likely reflecting a very mild form of asthma. For our statistical analysis, a repeated measure two-way ANOVA would have been the ideal test to compare our healthy and asthmatic populations. However, as our sample size was small, the power of this test turned out to be extremely low. Therefore, we opted to use both paired and unpaired comparisons with student's *t*-tests in this study. All the results we report as being statistically significant, the power of the test is 0.8 or higher. Finally, our analytic measures of ventilation heterogeneity only quantified ventilated lung regions, namely regions that are not completely closed off. To include lung regions that are completely closed in severe bronchoconstriction, we recommend the use of ^1^H proton images for the segmentation of the entire thoracic cavity. However, such a method may pose some difficulty in extracting and distilling out the contribution of the trachea and major airways. In addition, due to technical limitations, imaging and lung mechanics measurements were not acquired in identical positions. Lung mechanics measurements vary with position where lung compliance has been found to decrease from sitting to supine while lung resistance has been found to increase \[[@pone.0142738.ref045]\]. However, when utilizing a forced oscillation technique to measure respiratory system resistance and elastance, these parameters do not change significantly in the sitting and supine position in past studies \[[@pone.0142738.ref018]\]. Ideally, for a direct one-to-one comparison, lung mechanics and imaging should be acquired in identical positions.

Conclusion {#sec014}
----------

In summary, in this study we advance a quantification of ventilation heterogeneity from HP ^3^He-MRI showing an agreement to measurements of dynamic lung mechanics. Our findings from dynamic lung mechanics were consistent with the notion of peripheral rather than central involvement of ventilation heterogeneity. Furthermore, our results demonstrate a strong link between the degree of baseline ventilation heterogeneity and AHR which may be of potential clinical use in evaluating for baseline asthma in instances where a Mch- challenge may not be suitable. In addition, recent clinical studies have shown that measurement of ventilation heterogeneity can be used as a predictor of the symptomatic response of asthmatic patients to changes in inhaled corticosteroid dose \[[@pone.0142738.ref039]\]. All-in-all, our technique is capable of delivering both structural and functional information that can be applied to tracking response to asthma therapy.
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